Navigation Links
CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes
Date:9/2/2009

VIENNA, Va., Sept. 2 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM), a developer of vaccines for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the elimination of Series K convertible notes (the "Notes"). The Notes, which had an initial principal value of $8.3 million, were issued in August 2006, and were convertible into common stock.

"The elimination of the Notes significantly strengthens the Company's balance sheet and removes a potential overhang for our shareholders," said Geert Kersten, CEL-SCI Corporation's Chief Executive Officer. "Over the past three months, we have considerably improved our financial condition, allowing us to move forward in the development of several of our promising clinical platforms."

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a vaccine to prevent and treat swine and other influenzas using its L.E.A.P.S.(TM) technology platform and expects to soon finish the validation of its state-of-the-art facility in Maryland which it expects to utilize to launch aseptic filling for stem cell produced therapies and other biological products. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.

For more information, please visit www.cel-sci.com.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CEL-SCI Completes $5.85 Million Registered Direct Offering
2. CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
3. CEL-SCI Expands Testing of Its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses
4. CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results
5. CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
6. CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
7. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
8. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
9. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
10. CEL-SCI Corporation Releases Letter to Shareholders
11. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... March is ... that pack a punch when it comes to maintaining good health. Every day, two ... minutes, your kidneys filter every drop of your blood, eliminating waste, regulating fluid levels ...
(Date:3/23/2017)... ... ... The TouchPoint Solution, home of Buzzies *, is boosting the Arizona economy ... change the way we interact with stress and live our day-to-day lives,” said Dr. ... December 2016, The TouchPoint Solution has sold more than $750,000 in product sales. The ...
(Date:3/23/2017)... ... 2017 , ... ?This conference will prominently feature 150+ Hospital and Health System Executive Speakers including: ... Salka , 43rd President of the United States of America: George W. Bush ... and Out of the Ring: Sugar Ray Leonard , JD, Chairperson, McGuireWoods LLP: ...
(Date:3/23/2017)... ... , ... It’s that time of year again! Time to think about summer ... , which can be frustrating when they don’t even know how to begin describing ... public relations firm outside of Philadelphia, have offered these three tips to make the ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 ... Pharmaceutical and Healthcare disease pipeline guide Primary Hyperoxaluria ... of the Primary Hyperoxaluria (Genito Urinary System And ... a rare condition characterized by recurrent kidney and ... a substance called oxalate. Symptoms include blood in ...
(Date:3/23/2017)... , March 23, 2017  Digital Pharmacist ... ), a rapidly growing digital health company, ... mobile app that allows patients to manage their ... locations such as Denver Health Pharmacy, USave Pharmacy ... acquisition helps Digital Pharmacist accelerate its product development ...
(Date:3/23/2017)... -- Ethicon* today announced the completion of its acquisition ... device company that manufactures and markets the LINX™ ... Gastroesophageal Reflux Disease (GERD). This acquisition is aligned ... minimally invasive options for patients suffering from prevalent ... transaction have not been disclosed. ...
Breaking Medicine Technology: